Comparative Pharmacology
Head-to-head clinical analysis: CORDARONE versus IBUTILIDE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDARONE versus IBUTILIDE FUMARATE.
CORDARONE vs IBUTILIDE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs action potential duration and refractory period via blockade of potassium channels; also exhibits class I, II, and IV properties including sodium channel blockade, non-competitive beta-adrenergic blockade, and calcium channel blockade.
Ibutilide fumarate is a Class III antiarrhythmic agent that prolongs the atrial and ventricular refractory period by blocking the rapid component of the delayed rectifier potassium current (IKr) and also enhances the slow inward sodium current (INa), resulting in prolongation of the action potential duration and effective refractory period.
Loading dose: 800-1600 mg/day orally in divided doses for 1-3 weeks, then 600-800 mg/day for 1 month, then maintenance: 200-400 mg/day. IV: Loading 150 mg over 10 minutes, then 1 mg/min for 6 hours, then 0.5 mg/min.
1 mg (10 mL of 0.1 mg/mL solution) IV infusion over 10 minutes; if arrhythmia persists after 10 minutes post-infusion, a second 1 mg dose may be administered. For patients weighing <60 kg, use 0.01 mg/kg.
None Documented
None Documented
Terminal half-life ranges 40–70 days (mean 55 days) due to extensive tissue accumulation, particularly in adipose tissue. Prolonged half-life necessitates loading doses and long washout periods.
Terminal elimination half-life is 2–12 hours (mean 6 hours). In atrial fibrillation/flutter, the clinically effective half-life allowing for arrhythmia conversion is approximately 2–4 hours due to rapid redistribution.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<1% unchanged). Fecal excretion accounts for ~70% of the dose. Less than 10% excreted in urine.
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20% of total clearance.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)